Andrew Wood

7.0k total citations
78 papers, 2.4k citations indexed

About

Andrew Wood is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Andrew Wood has authored 78 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Neurology. Recurrent topics in Andrew Wood's work include Neuroblastoma Research and Treatments (14 papers), Cancer therapeutics and mechanisms (7 papers) and Acute Myeloid Leukemia Research (5 papers). Andrew Wood is often cited by papers focused on Neuroblastoma Research and Treatments (14 papers), Cancer therapeutics and mechanisms (7 papers) and Acute Myeloid Leukemia Research (5 papers). Andrew Wood collaborates with scholars based in United States, United Kingdom and New Zealand. Andrew Wood's co-authors include John M. Maris, Yaël P. Mossé, Seongeun Cho, Mark R. Bowlby, Kristina A. Cole, Mike R. Russell, Sharon J. Diskin, Mark A. Lemmon, Edward F. Attiyeh and Scott C. Bresler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Andrew Wood

73 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Wood United States 22 1.1k 713 699 532 416 78 2.4k
Dicky Halley Netherlands 36 1.8k 1.7× 383 0.5× 678 1.0× 714 1.3× 211 0.5× 129 5.2k
Thomas Mathivet France 26 1.5k 1.4× 327 0.5× 440 0.6× 373 0.7× 277 0.7× 43 3.1k
Kyung‐Hwa Lee South Korea 25 840 0.8× 293 0.4× 483 0.7× 274 0.5× 371 0.9× 179 2.3k
Rakesh Nagarajan United States 30 1.8k 1.7× 297 0.4× 332 0.5× 282 0.5× 812 2.0× 60 3.3k
Elisabet Wallgard Sweden 7 2.0k 1.8× 427 0.6× 449 0.6× 260 0.5× 421 1.0× 7 3.8k
Zhaohai Yang United States 25 850 0.8× 562 0.8× 1.1k 1.6× 169 0.3× 210 0.5× 78 2.9k
Takanori Ohnishi Japan 33 1.1k 1.0× 775 1.1× 480 0.7× 325 0.6× 485 1.2× 146 3.5k
Ituro Inoue Japan 35 1.5k 1.4× 305 0.4× 383 0.5× 235 0.4× 574 1.4× 101 3.6k
Jenny Norlin Sweden 13 1.2k 1.1× 312 0.4× 340 0.5× 222 0.4× 231 0.6× 20 3.0k
Arzu Onar‐Thomas United States 33 1.2k 1.1× 966 1.4× 615 0.9× 631 1.2× 395 0.9× 130 3.3k

Countries citing papers authored by Andrew Wood

Since Specialization
Citations

This map shows the geographic impact of Andrew Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Wood more than expected).

Fields of papers citing papers by Andrew Wood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Wood. The network helps show where Andrew Wood may publish in the future.

Co-authorship network of co-authors of Andrew Wood

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Wood. A scholar is included among the top collaborators of Andrew Wood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Wood. Andrew Wood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lints, Robyn, et al.. (2024). Mutational cooperativity of RUNX1::RUNX1T1 isoform 9a and oncogenic NRAS in zebrafish myeloid leukaemia. Biology Open. 13(9). 1 indexed citations
2.
Campbell, Rebecca A., Andrew Wood, Zeyad Schwen, et al.. (2024). MRI and active surveillance: thoughts from across the pond. European Radiology. 35(4). 2157–2169.
3.
Lovell, Amy L., et al.. (2023). Nutrition screening, assessment, and intervention practices for children with cancer in Aotearoa, New Zealand. Nutrition. 116. 112218–112218. 6 indexed citations
4.
Wood, Andrew, Rebecca A. Campbell, Reza Alaghehbandan, et al.. (2023). Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology. Urologic Oncology Seminars and Original Investigations. 42(3). 71.e1–71.e7. 3 indexed citations
5.
Rathi, Nityam, Yosuke Yasuda, Carlos Muñoz-López, et al.. (2023). Practical Prediction of New Baseline Renal Function After Partial Nephrectomy. Annals of Surgical Oncology. 31(2). 1402–1409. 4 indexed citations
6.
Taslim, Cenny, Jesse C. Crow, Peter Heppner, et al.. (2021). Identification of a Novel FUS/ETV4 Fusion and Comparative Analysis with Other Ewing Sarcoma Fusion Proteins. Molecular Cancer Research. 19(11). 1795–1801. 11 indexed citations
7.
8.
Bailey, Damian M., M. H. Lewis, Andrew C. Gordon, et al.. (2021). When is extra-anatomical bypass for the left subclavian artery required to prevent ischaemia after thoracic endovascular stent grafting?. Asian Cardiovascular and Thoracic Annals. 29(6). 524–531. 1 indexed citations
9.
Trahair, Toby N., Andrew J. Gifford, Chelsea Mayoh, et al.. (2019). Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors. JCO Precision Oncology. 3(3). 1–11. 33 indexed citations
10.
Hart, Lori S., JulieAnn Rader, Pichai Raman, et al.. (2016). Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research. 23(7). 1785–1796. 57 indexed citations
11.
Wood, Andrew, Kateryna Krytska, Hannah T. Ryles, et al.. (2016). Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. Clinical Cancer Research. 23(11). 2856–2868. 67 indexed citations
12.
Wood, Andrew, Thomas Mentzel, Joost van Gorp, et al.. (2014). The spectrum of rare morphological variants of cutaneous epithelioid angiosarcoma. Histopathology. 66(6). 856–863. 17 indexed citations
13.
Rader, JulieAnn, Mike R. Russell, Lori S. Hart, et al.. (2013). Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research. 19(22). 6173–6182. 308 indexed citations
14.
Rader, JulieAnn, Lori S. Hart, Mike R. Russell, et al.. (2013). Abstract 2744: CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas.. Cancer Research. 73(8_Supplement). 2744–2744. 4 indexed citations
15.
Mayes, Patrick A., Yan Degenhardt, Andrew Wood, et al.. (2012). Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition. International Journal of Cancer. 132(3). 16 indexed citations
16.
Balamuth, Naomi, Andrew Wood, Qun Wang, et al.. (2010). Serial Transcriptome Analysis and Cross-Species Integration Identifies Centromere-Associated Protein E as a Novel Neuroblastoma Target. Cancer Research. 70(7). 2749–2758. 41 indexed citations
17.
Mossé, Yaël P., Andrew Wood, & John M. Maris. (2009). Inhibition of ALK Signaling for Cancer Therapy. Clinical Cancer Research. 15(18). 5609–5614. 124 indexed citations
18.
19.
Cho, Seongeun, Andrew Wood, & Mark R. Bowlby. (2007). Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics. Current Neuropharmacology. 5(1). 19–33. 188 indexed citations
20.
Wood, Andrew, et al.. (1996). Patterns of supradiaphragmatic metastases in testicular germ cell tumours. Clinical Radiology. 51(4). 273–276. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dicky Halley Breakdown of academic impact, for papers by Thomas Mathivet Breakdown of academic impact, for papers by Kyung‐Hwa Lee Breakdown of academic impact, for papers by Rakesh Nagarajan Breakdown of academic impact, for papers by Elisabet Wallgard Breakdown of academic impact, for papers by Zhaohai Yang Breakdown of academic impact, for papers by Takanori Ohnishi Breakdown of academic impact, for papers by Ituro Inoue Breakdown of academic impact, for papers by Jenny Norlin Breakdown of academic impact, for papers by Arzu Onar‐Thomas
Rankless by CCL
2026